Sleep disruption has long been recognized as a devastating symptom of Alzheimer's disease, but until now, scientists did not know exactly what caused it. The prevailing theory held that the progressive loss of neurons or the accumulation of sticky amyloid plaques physically interfered with the brain's sleep circuitry. A new study published in Alzheimer's & Dementia by researchers at the University of Kentucky has turned that assumption on its head.
The team, led by Dr. Shannon Macauley and first author Dr. Nicholas Constantino, discovered that microglia — the brain's resident immune cells — are the real culprits. When amyloid plaques begin forming in the early stages of Alzheimer's, microglia swarm to the site and launch an inflammatory response. The researchers describe this as a "house-wide sprinkler system" activating in response to a small kitchen fire: the intended protective mechanism ends up causing widespread collateral damage.
"Microglia are immune cells that, when they respond to plaques, kick off this elaborate cascade of inflammation, as if the microglia are partying all night, and keeping the brain awake," Macauley said. Using sophisticated EEG monitoring and light-sheet microscopy — a technique that makes brain tissue transparent to create 3D maps — the team tracked exactly where and when these immune cells were most active.
To prove that microglia were the direct cause of sleep disruption, the researchers used a drug called Pexidartinib (PLX3397) to temporarily remove 87 percent of the brain's microglia over a 14-day period. The result was dramatic: mice with Alzheimer's pathology gained more than two hours of sleep per night. Their deep, restorative non-REM sleep bouts became longer, allowing more opportunities to transition into healthy REM sleep for memory consolidation.
Perhaps the most surprising finding was what the researchers call a "ceiling effect." When they compared mice at six months of age (when plaques first emerge) to mice at 18 months (with more than double the plaque burden), the level of sleep disruption was essentially the same. This suggests that the initial immune storm triggered by early plaque formation — not the plaques themselves — causes the damage, and that the damage is set early in the disease process.
The study also drew a clear distinction between normal aging and Alzheimer's-related sleep changes. Normal aging selectively reduces REM sleep — the dreaming stage critical for memory consolidation. Alzheimer's pathology, on the other hand, selectively targets non-REM sleep — the deep, restorative stage that the brain uses for physical repair and clearing out metabolic waste products. "When Alzheimer's patients lose this stage, they lose their brain's primary cleaning cycle, creating a feed-forward loop that may drive further damage," Macauley explained.
This discovery opens an entirely new avenue for treating Alzheimer's symptoms. Rather than targeting amyloid plaques directly — an approach that has shown limited clinical success — future therapies could focus on modulating the immune response in the brain. If microglial activity can be calmed without fully eliminating them, patients may be able to regain the restorative sleep that is essential for cognitive function and quality of life.